Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Status:
Completed
Trial end date:
2015-10-21
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of a single injection of NX-1207
for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients
currently undergoing active surveillance. Study participants currently on active surveillance
will be randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5
mg or 15 mg) followed by active surveillance or to no treatment (continued active
surveillance). Blinded efficacy evaluation will be by a second post-treatment prostate
biopsy.